^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-8543

    i
    Other names: JNJ-8543, JNJ-80948543, JNJ80948543, JNJ8543, JNJ 80948543, JNJ 8543
    Associations

    News

    Trials
    Company:
    J&J
    Drug class:
    CD20 inhibitor, CD3 agonist, CD79B inhibitor
    Related drugs:
    Associations

    News

    Trials
    9d
    Characterization of JNJ-80948543 a novel CD79bxCD20xCD3 trispecific antibody for B-cell non-Hodgkin lymphoma. (PubMed, Haematologica)
    Collectively, the selectivity, potent cytotoxicity, tumor growth inhibition, and favorable cytokine profile of JNJ-80948543 supports its clinical development. Phase 1 clinical trials are ongoing to evaluate JNJ-80948543 as a monotherapy (NCT05424822) and in combination with a co-stimulatory bispecific antibody (NCT06139406) in patients with R/R B-NHL.
    Journal
    |
    CD79B (CD79b Molecule)
    |
    JNJ-8543
    21d
    A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2026 --> Sep 2026
    Trial primary completion date
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    2ms
    A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=167, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jun 2026 --> Oct 2025
    Trial primary completion date • First-in-human
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-8543
    2ms
    A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Sep 2026 --> Jan 2026
    Trial primary completion date
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    2ms
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=235 --> 70 | Trial completion date: Nov 2027 --> Aug 2026 | Trial primary completion date: Nov 2027 --> Jan 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    4ms
    A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=40 --> 19
    Enrollment closed • Enrollment change
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    8ms
    A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=167, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | Trial completion date: Nov 2026 --> Jul 2027
    Enrollment closed • Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-8543
    8ms
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=235, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jul 2026 --> Nov 2027
    Trial primary completion date
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    9ms
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=235, Recruiting, Janssen Research & Development, LLC | N=70 --> 235 | Trial completion date: Jul 2026 --> Nov 2027
    Enrollment change • Trial completion date
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    over1year
    A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (clinicaltrials.gov)
    P1, N=40, Recruiting, Janssen Research & Development, LLC
    New P1 trial • Combination therapy
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    over1year
    A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=220, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jul 2024 --> Jun 2026
    Trial primary completion date • Trispecific
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-8543
    2years
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=70, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2026
    Enrollment open • Trial completion date • Combination therapy
    |
    JNJ-8543 • rezetamig (JNJ-8780)